The role involves delivering commercial insights to inform strategic choices for genetic kidney disease assets including inaxaplin.
Base: $157,800 - $236,600; Bonus/Equity: Eligible for annual bonus and equity awards; Benefits: Medical, dental, vision, PTO, 401(k), student loan repayment
Must-have
Nice-to-have
Not specified